These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459 [TBL] [Abstract][Full Text] [Related]
4. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Pandruvada SN; Yuvaraj S; Liu X; Sundaram K; Shanmugarajan S; Ries WL; Norris JS; London SD; Reddy SV Int J Cancer; 2010 May; 126(10):2319-29. PubMed ID: 19816883 [TBL] [Abstract][Full Text] [Related]
5. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Zhang X; Junior CR; Liu M; Li F; D'Silva NJ; Kirkwood KL Oral Oncol; 2013 Feb; 49(2):119-28. PubMed ID: 22989723 [TBL] [Abstract][Full Text] [Related]
6. Characterization of bone resorption in novel in vitro and in vivo models of oral squamous cell carcinoma. Martin CK; Dirksen WP; Shu ST; Werbeck JL; Thudi NK; Yamaguchi M; Wolfe TD; Heller KN; Rosol TJ Oral Oncol; 2012 Jun; 48(6):491-9. PubMed ID: 22265717 [TBL] [Abstract][Full Text] [Related]
7. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Sambandam Y; Sundaram K; Liu A; Kirkwood KL; Ries WL; Reddy SV Oncogene; 2013 Jan; 32(1):97-105. PubMed ID: 22330139 [TBL] [Abstract][Full Text] [Related]
8. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. Hwang YS; Lee SK; Park KK; Chung WY Oral Oncol; 2012 Jan; 48(1):40-8. PubMed ID: 21925926 [TBL] [Abstract][Full Text] [Related]
9. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. Tohyama R; Kayamori K; Sato K; Hamagaki M; Sakamoto K; Yasuda H; Yamaguchi A J Oral Pathol Med; 2016 May; 45(5):356-64. PubMed ID: 26859422 [TBL] [Abstract][Full Text] [Related]
13. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma. Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842 [TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of NF-κB suppresses bone invasion by oral squamous cell carcinoma in vivo. Furuta H; Osawa K; Shin M; Ishikawa A; Matsuo K; Khan M; Aoki K; Ohya K; Okamoto M; Tominaga K; Takahashi T; Nakanishi O; Jimi E Int J Cancer; 2012 Sep; 131(5):E625-35. PubMed ID: 22262470 [TBL] [Abstract][Full Text] [Related]
15. Molecular pathways involved in crosstalk between cancer cells, osteoblasts and osteoclasts in the invasion of bone by oral squamous cell carcinoma. Quan J; Zhou C; Johnson NW; Francis G; Dahlstrom JE; Gao J Pathology; 2012 Apr; 44(3):221-7. PubMed ID: 22406484 [TBL] [Abstract][Full Text] [Related]
16. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo. Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094 [TBL] [Abstract][Full Text] [Related]
17. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer. Russmueller G; Moser D; Würger T; Wrba F; Christopoulos P; Kostakis G; Seemann R; Stadler V; Wimmer G; Kornek G; Psyrri A; Filipits M; Perisanidis C Oral Oncol; 2015 Mar; 51(3):247-53. PubMed ID: 25532817 [TBL] [Abstract][Full Text] [Related]
19. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review). Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319 [TBL] [Abstract][Full Text] [Related]
20. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]